BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) insider Henry J. Fuchs sold 5,932 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $87.86, for a total value of $521,185.52. Following the completion of the transaction, the insider now directly owns 130,468 shares in the company, valued at $11,462,918.48. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
NASDAQ:BMRN opened at $87.81 on Friday. The company has a quick ratio of 2.92, a current ratio of 3.93 and a debt-to-equity ratio of 0.28. BioMarin Pharmaceutical Inc. has a 52 week low of $75.81 and a 52 week high of $106.74.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, February 21st. The biotechnology company reported ($0.02) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.07. The business had revenue of $353.00 million for the quarter, compared to analysts’ expectations of $377.35 million. BioMarin Pharmaceutical had a negative return on equity of 2.79% and a negative net margin of 5.18%. The business’s quarterly revenue was down 1.4% on a year-over-year basis. During the same period last year, the firm earned $0.03 earnings per share. Equities research analysts expect that BioMarin Pharmaceutical Inc. will post 0.02 earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of the company. Norges Bank bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter worth about $101,134,000. Dimensional Fund Advisors LP increased its holdings in shares of BioMarin Pharmaceutical by 7.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 309,779 shares of the biotechnology company’s stock worth $26,375,000 after purchasing an additional 21,009 shares during the last quarter. Sofinnova Investments Inc. bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter worth about $11,968,000. Lake Point Wealth Management bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter worth about $34,000. Finally, YorkBridge Wealth Partners LLC increased its holdings in shares of BioMarin Pharmaceutical by 76.7% in the fourth quarter. YorkBridge Wealth Partners LLC now owns 606 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 263 shares during the last quarter.
A number of equities analysts recently commented on the company. BidaskClub cut BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Friday, March 22nd. ValuEngine cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, March 21st. Cantor Fitzgerald raised their target price on BioMarin Pharmaceutical to $131.00 and gave the stock an “overweight” rating in a report on Monday, March 4th. Zacks Investment Research cut BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, March 1st. Finally, Wedbush set a $127.00 target price on BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Tuesday, February 26th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $112.82.
ILLEGAL ACTIVITY WARNING: “BioMarin Pharmaceutical Inc. (BMRN) Insider Henry J. Fuchs Sells 5,932 Shares” was originally posted by Macon Daily and is the property of of Macon Daily. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://macondaily.com/2019/03/29/biomarin-pharmaceutical-inc-bmrn-insider-henry-j-fuchs-sells-5932-shares.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
Further Reading: What is an investor looking for in an SEC filing?
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.